May 27, 2021Catheterization and Cardiovascular Interventions

Sarcopenia index as a predictor of clinical outcomes in older patients undergoing transcatheter aortic valve replacement

View Full Paper

Ask AI

Bookmark

Why the study?

Sarcopenia is prevalent in elderly patients and linked to adverse outcomes after TAVR, but the predictive value of the serum creatinine-cystatin C ratio (Sarcopenia Index) remained to be determined.

Does a low Sarcopenia Index predict all-cause mortality and/or heart failure readmissions in older patients undergoing TAVR?

Structured PICO

Does a low Sarcopenia Index predict all-cause mortality and/or heart failure readmissions in older patients undergoing TAVR?

Population

100 patients ≥65 years old undergoing transcatheter aortic valve replacement (TAVR) at a single center in Argentina. Excluded: previous surgical aortic valve replacement, severe chronic kidney disease, or hemodialysis requirement.

Intervention

Low Sarcopenia Index (serum creatinine-cystatin C ratio ≤66) measured at baseline before TAVR

Comparator

Higher Sarcopenia Index (>66)

Outcome

Composite of all-cause mortality and/or readmissions for congestive heart failure (CHF) at 1-year follow-upcomposite

The Sarcopenia Index (serum creatinine-cystatin C ratio) is a useful surrogate marker for skeletal muscle mass that independently predicts 1-year mortality and heart failure readmissions in older patients undergoing TAVR.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

SI may flag higher-risk TAVR patients for monitoring; leaves open prospective validation and incremental prognostic value.

Cite This Study

Romeo et al. (2021) studied this question.

synapsesocial.com/papers/6a73c006f4f9256fee8de414 https://doi.org/10.1002/ccd.29799

Topics

TAVR in low-risk patients Transcatheter aortic valve replacement

View Full Paper

Ask AI

Bookmark